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Background: Increasing evidence indicates an important role of transcription factor Yin Yang-1 (YY1) in human
tumorigenesis. However, its function in cancer remains controversial and the relevance of YY1 to pancreatic ductal
adenocarcinoma (PDAC) remains to be clarified.
Methods: In this study, we detected YY1 expression in clinical PDAC tissue samples and cell lines using quantitative
RT-PCR, immunohistochemistry and western blotting. We also detected MUC4 and MMP10 mRNA levels in 108
PDAC samples using qRT-PCR and analyzed the correlations between YY1 and MUC4 or MMP10 expression. The role
of YY1 in the proliferation, invasion and metastatic abilities of PDAC cells in vitro was studied by CCK-8 assay, cell
migration and invasion assays. In vivo pancreatic tumor growth and metastasis was studied by a xenogenous
subcutaneously implant model and a tail vein metastasis model. The potential mechanisms underlying YY1 mediated
tumor progression in PDAC were explored by digital gene expression (DGE) sequencing, signal transduction pathways
blockage experiments and luciferase assays. Statistical analysis was performed using the SPSS 15.0 software.
Results: We found that the expression of YY1 in PDACs was higher compared with their adjacent non-tumorous tissues
and normal pancreas tissues. However, PDAC patients with high level overexpression of YY1 had better outcome
than those with low level overexpression. YY1 expression levels were statistically negatively correlated with MMP10
expression levels, but not correlated with MUC4 expression levels. YY1 overexpression suppressed, whereas YY1
knockdown enhanced, the proliferation, invasion and metastatic properties of BXPC-3 cells, both in vitro and
in vivo. YY1 suppresses invasion and metastasis of pancreatic cancer cells by downregulating MMP10 in a MUC4/
ErbB2/p38/MEF2C-dependent mechanism.
Conclusions: The present study suggested that YY1 plays a negative role, i.e. is a tumor suppressor, in PDAC,
and may become a valuable diagnostic and prognostic marker of PDAC.
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Pancreatic ductal adenocarcinoma (PDAC) is one of the
most deadly cancers in the world. The survival time is
extremely short (6 months) and the survival rate at 5
years is very low (3%) [1]. This poor outcome is related
to a lack of efficient therapeutic tools and early diag-
nostic markers. At the time of diagnosis, more than
80% of PDAC patients are already metastatic or have
locally advanced cancer, and only about 10% to 15% of
patients are considered eligible for surgical resection
[2]. Chemotherapy is often either ineffective or effective
only for a short duration. Further therapeutic approaches
are needed in addition to conventional chemotherapy
for this deadly disease. Molecular-targeted therapy,
including activation of tumor suppressor genes, and/or
repression of oncogenes, is an attractive therapeutic
addition to regular chemotherapies. Thus, it is very
important to find new therapeutic molecular targets of
PDAC.
Yin Yang-1 (YY1) is a ubiquitously expressed, multi-
functional zinc finger transcription factor that belongs
to the GLI-Kruppel family of nuclear proteins [3]. YY1
has a fundamental role in biological and physiological
processes, such as embryogenesis, cellular proliferation,
DNA replication and differentiation [3-5]. YY1 can act
as a transcriptional activator, repressor or initiator pro-
tein depending upon DNA binding site context or cell
type [6-9]. Increasing evidence indicates an important
role of YY1 in human tumorigenesis. However, the data
are somewhat diverse, with some cancers showing in-
creased YY1 expression and some showing decreased
expression. For example, increased YY1 expression was
observed in cancers of the prostate, ovary, colon, breast,
bone, liver, lung, bladder, cervix and blood [10-19]. Re-
duced YY1 expression was found in some melanomas,
pediatric osteosarcomas and urothelial carcinomas [15].
In addition, conflicting data exist on the survival out-
come in relation to YY1 expression. In some cases, high
expression of YY1 correlated with poor prognosis (such as
in prostate, breast and bone cancers) [10,13,20], whereas in
other situations, YY1 expression correlated with favor-
able outcomes (such as in ovarian cancer, colon cancer
and follicular lymphoma) [11,12,21]. These studies in-
dicated strongly the important role of YY1 in cancer
development. However, the relevance of YY1 to PDAC
remains to be clarified. We thus proposed to study YY1
expression in clinical PDAC samples and the potential
mechanisms underlying YY1 mediated tumor progres-
sion in PDAC. In this study, we found that the expres-
sion of YY1 in PDACs was higher compared with their
adjacent non-tumorous tissues and normal pancreas
tissues. However, PDAC patients with high level over-
expression of YY1 had better outcome than those with
low level overexpression. YY1 overexpression suppressed,whereas YY1 knockdown enhanced, the proliferation,
invasion and metastatic properties of BXPC-3 cells. YY1
suppresses invasion and metastasis of pancreatic cancer
cells by downregulating MMP10 in a MUC4/ErbB2/
p38/MEF2C-dependent mechanism. These results indi-
cated that YY1 might become a valuable diagnostic and
prognostic marker for PDAC.
Results
YY1 expression in PDAC tissues and cell lines
We measured YY1 mRNA expression in five normal
pancreas tissue samples and in 108 PDAC tissue samples
with paired adjacent non-tumorous tissue using qRT-
PCR. As observed in Figure 1a and b, YY1 expression in
the normal pancreas tissue samples was low, but was
slightly higher in the tissue adjacent to PDAC tumors
and significantly higher in the PDAC tumors themselves.
Of the 108 paired samples, 87 (80.6%) showed signi-
ficantly higher YY1 expression in the tumor tissues
compared with the adjacent tissues (p < 0.05). The same
trend could be observed using a boxplot (Figure 1c),
which showed that the mean expression level of YY1 in
tumors, tumor adjacent normal tissues and normal
pancreas was 1.01 ± 1.01, 0.38 ± 0.43 and 0.03 ± 0.01,
respectively. We then detected YY1 mRNA and protein
expression in PDAC cell lines. As observed in Figure 1d,
of the six cell lines tested, HPAC and SW1990 expressed
YY1 at high levels, BXPC-3 and CFPAC-1 expressed YY1
at moderate levels, and PANC-1 and COLO-357 cells
showed low levels of YY1 expression. In addition, the
western blotting results agreed with the results of qRT-
PCR (Figure 1e). We then detected YY1 protein expres-
sion in clinical samples using immunohistochemistry.
The results (Figure 1f ) showed that YY1 protein expres-
sion in the normal pancreas tissue samples was low, but
was slightly higher in the tissue adjacent to PDAC tumors
and significantly higher in the PDAC tumors themselves,
which agreed with the results of qRT-PCR. From Figure 1g,
we observed that YY1 was located in the nucleus and
cytoplasm of tumor cells. Moreover the YY1 RNA levels
(qRT-PCR results) were statistically correlated with pro-
tein levels (IHC results) ((r = 0.854, p < 0.001). Taken
together, our results show that YY1 is highly expressed
in PDAC tissues, indicating that YY1 might be activated
during pancreatic tumorigenesis and may have an im-
portant role in PDAC.
Correlations between YY1 mRNA expression and
clinicopathological or serological variables of PDAC
patients
Correlations between YY1 mRNA expression and clini-
copathological or serological characteristics in PDACs
from all 108 patients are shown in Table S1 (Additional
file 1). YY1 expression was statistically correlated with
Figure 1 YY1 expression in PDAC tissues and cell lines. (a, b) qRT-PCR analysis of YY1 expression in five normal pancreas tissues and 108 pairs
of PDAC tissue and adjacent tissue. YY1 expression in the normal pancreas tissues was low, but was slightly higher in the tissue adjacent to PDAC
tumors and significantly higher in the PDAC tumors themselves. Of the 108 paired tissues, YY1 expression was higher in the cancer tissue than
in the adjacent tissues in 86 cases (p < 0.05). (c) A boxplot showing the qRT-PCR results of YY1 mRNA expression in the 108 cancer tissue, 108
adjacent tissue and five normal pancreas tissues (mean ± SD: 1.01 ± 1.01, 0.38 ± 0.43 and 0.03 ± 0.01, respectively). The bottom and the top edges
of the box mark the lower boundary and upper boundary of the 95% confidence interval (CI) for the mean. The center horizontal line is drawn at
the sample mean. The center vertical lines drawn from the boxes extend to the minimum and the maximum. (d) qRT-PCR analysis of YY1 expression in
six PDAC cell lines. (e) Western blotting of YY1 expression in six PDAC cell lines. (f) A boxplot showing the immunohistochemistry (IHC) results of YY1
protein expression in the 108 cancer tissue, 108 adjacent tissue and five normal pancreas tissues. (g) IHC showing the location of YY1 in PDAC samples.
Scale bar, 100 μm. (** represents p < 0.01, # represents p < 0.001, compared with the control group).
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and p = 0.008, respectively). Elevated YY1 expression is
enriched in well-differentiated tumors, in lower TNM
grades and in tumors in young patients. No significant
correlations were identified between YY1 expression
and other variables.YY1 is an independent predictor of favorable outcome of
PDAC patients
One hundred and eight PDAC patients were enrolled in
the survival analysis. Eighty-four patients died, while
the remaining 24 patients were alive at the last follow
up (31 March 2013). To determine the YY1 expression
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divided into two groups based on the length of overall sur-
vival: short-term survivors (survival period < 24 months)
and long-term survivors (≥24 months). The threshold
value of 1.159 was chosen as the cut-off value for high and
low level overexpression of YY1, because 1.159 (within
95% confidence interval (CI), 0.821-1.208, of YY1 mRNA
expression) was on the ROC curve closest to (0.0, 1.0).
This maximized both sensitivity and specificity for the
survival outcome (Figure 2a). The area under the ROC
curve (AUC) was 0.858 (95% CI, 0.773-0.943, p < 0.001).
The Kaplan-Meier survival curves showed that patients
with high level (≥1.159) overexpression of YY1 had longer
post-operative survival than those with low level (<1.159)
overexpression (Figure 2b, p < 0.001, log rank test). The
two-year survival of patients with high-level overexpression
of YY1 was 37.9%. This was significantly higher than that of
patients with low-level overexpression (3.1%).
Meanwhile, based on 0.10 as the cut off p-value, seven
factors (location of tumor, tumor differentiation, TNM
staging, serum CA19-9, serum CA50, serum CEA and
YY1 expression) were selected from the univariate ana-
lysis data (Additional file 2: Table S2) for forward andFigure 2 Correlation between YY1 expression and patient survival. (a
low level YY1 expression. (b) Kaplan-Meier survival curves in 108 patients w
was calculated by the Log-rank test.backward stepwise multivariate Cox’s proportional
hazard analysis. Table 1 shows that tumor differenti-
ation (p = 0.022, p = 0.007, respectively), serum CA19-9
(p = 0.036, p = 0.028, respectively) and YY1 expression
(p = 0.004, p = 0.032, respectively) were significant inde-
pendent risk factors for predicting the prognosis of PDAC
patients. These results indicated that higher overexpres-
sion of YY1 predicted better outcome in PDAC patients,
although YY1 expression increased in PDAC tissues.
Generation of stable transfected cells
To further investigate the roles of YY1 in PDAC, we over-
expressed and silenced YY1 expression. BXPC-3 cells with
a moderate level of YY1 expression were chosen for these
experiments. We constructed YY1 overexpression and
YY1 knockdown lentiviruses to infect BXPC-3 cells and
selected stably infected cells. We confirmed the YY1
expression levels using qRT-PCR and western blotting
(Figure 3a and 3b).
YY1 suppresses proliferation of BXPC-3 cells in vitro
To investigate the effect of YY1 overexpression or knock-
down on BXPC-3 cell proliferation in vitro, we employed) ROC curve for YY1 expression and cut-off value selection for high and
ith PDAC according to their YY1 mRNA expression status. The p value
Table 1 Multivariate analysis of prognostic factors in PDAC patients (n = 108)
Variable Forward stepwisea Backward stepwiseb
HRc (95% CId) p HR (95% CI) p
Location of tumor 0.074 0.004*
Head - 1
Body and tail - 2.178 (1.274-3.725)
Differentiation 0.022* 0.007*
Well 1 1
Moderate 1.560 (0.681-3.572) 0.293 1.726 (0.752-3.961) 0.198
Poor 3.775 (1.302-10.943) 0.014* 4.807 (1.661-13.913) 0.004*
TNM staging 0.089 0.015*
IA + IB - 1
IIA - 0.804 2.694 (1.163-6.240) 0.021*
IIB - 0.666 2.892 (1.306-6.404) 0.009*
III + IV - 0.039 4.277 (1.746-10.476) 0.001*
Serum CA19-9 (kU/L) 0.036* 0.028*
≤ 39 1 1
> 39 1.803 (1.038-3.130) 1.881 (1.071-3.304)
YY1 0.004* 0.032*
Low level overexpression 1 1
High level overexpression 0.416 (0.229-0.756) 0.511 (0.277-0.944)
aForward stepwise, the parameters entered one by one, each time the parameter with the smallest p-value was entered, until the parameters not entered have no
significance; bBackward stepwise, all parameters entered the first-time, and then removed one by one, each time removing the parameter with the largest p-value,
until all of the parameters retained have significance; cHR, hazard ratio; d95% CI, 95% confidence interval; *p < 0.05.
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of YY1 on cell growth. As shown in Figure 3c, the curves
of growth according to absorbance indicated that YY1
overexpression significantly decreased the OD value com-
pared with the control group, while YY1 knockdown
significantly increased the OD value compared with the
control group. These results suggest a role for YY1 in the
negative regulation of BXPC-3 cell proliferation.
YY1 suppresses migration and invasion of BXPC-3 cells
in vitro
YY1 overexpression significantly suppressed the migra-
tion of BXPC-3 cells (BXPC-YY1 vs. BXPC-Vector,
0.142 ± 0.018 vs. 0.324 ± 0.022, p < 0.001) (Figure 3d and
3e). By contrast, YY1 knockdown promoted the migra-
tion of BXPC-3 cells (BXPC-YY1 shRNA vs. BXPC-
Scramble shRNA, 0.555 ± 0.033 vs. 0.271 ± 0.032, p <
0.001) (Figure 3d and 3e). Cell invasion assays showed
that YY1 overexpression significantly decreased the inva-
sion of BXPC-3 cells (BXPC-YY1 vs. BXPC-Vector,
0.1272 ± 0.024 vs. 0.285 ± 0.016, p < 0.001), while YY1
knockdown enhanced the invasion of BxPC-3 cells
(BXPC-YY1 shRNA vs. BXPC-Scramble shRNA, 0.470 ±
0.028 vs. 0.247 ± 0.013, p < 0.001) (Figure 3d and 3f).
These results suggest a role for YY1 in the negative
regulation of BXPC-3 cell migration and invasion.YY1 suppresses tumor growth and metastasis of BXPC-3
cells in vivo
To further study the effects of YY1 on tumorigenicity
and metastasis of PDAC, in vivo experiments were per-
formed via the subcutaneous or tail vein injection of
transduced cells into BALB/cA-nu nude mice. After in-
jection, in the xenograft tumor model, we measured
the size of the growing tumors weekly for four weeks,
after which the mice were euthanized. The tumor sizes
of the BXPC-YY1 shRNA group were significantly lar-
ger than the BXPC-Scramble shRNA group (Figure 4a).
The subcutaneous tumors were excised, stained using
HE stain and RNA extracted from them to confirm that
the stable knockdown of YY1 was maintained (Figure 4b
and 4c). In the tail vein metastasis model, lung or liver
metastases were observed in only two of the eight mice
injected with BXPC-YY1 cells. By contrast, metastases
were observed in seven of the eight mice injected with
BXPC-Vector cells (Table 2, Figure 4d). The statistical
analysis of the data showed a significant difference
between the BXPC-YY1 cells and BXPC-Vector cells
(p = 0.0406). In addition, in the xenograft models, no
metastasis was found in the BXPC-Scramble shRNA
control group, whereas there were two lung metastasis
in the BXPC-YY1 shRNA group. However, there was
no significant difference between the BXPC-YY1 shRNA
Figure 3 Effects of YY1 on the proliferation, migration and invasion of BXPC-3 cells in vitro. (a) Measurement of YY1 expression in stably
transfected BXPC-3 cells using qRT-PCR. BXPC-YY1 indicates YY1overexpressing BXPC-3 cells; BXPC-Vector indicates BXPC-3 cells transfected
with a control vector; BXPC-YY1 shRNA indicates YY1 knockdown BXPC-3 cells; BXPC-Scramble shRNA indicates BXPC-3 cells transfected
with a vector expressing Scramble shRNA. (b) Measurement of YY1 expression in stably transfected BXPC-3 cells using western blotting. The
results are similar to those seen in the qRT-PCR analysis. (c) CCK-8 assays were performed. OD values from four independent experiments
were assessed. (d) Cell migration and invasion assays were performed. The upper chambers were seeded with various cell lines. The
membranes of the chambers were stained with 0.1% crystal violet. Scale bar, 100 μm. (e, f) Quantification of the data from Figure 3d. OD values from
three independent experiments were assessed. (*represents p < 0.05, **represents p < 0.01, # represents p < 0.001, compared with the control group).
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The small number of samples in the experiment means
that the result needs further confirmation. These data
indicate that knockdown of YY1 significantly promotestumor growth, and overexpression of YY1 significantly
suppresses metastasis of BXPC-3 cells in vivo, indicating
that YY1 has a negative role in PDAC tumorigenicity and
metastasis.
Figure 4 Effects of YY1 on the tumor growth and metastasis of BXPC-3 cells in vivo. (a) BXPC-Scramble shRNA and BXPC-YY1 shRNA cells
were bilaterally injected into the flank region of the mice (1.5 × 106 cells/100 μl per flank). After injection, the length and width of the tumors were
measured every week. The volume of the tumors was calculated using the formula (width2 × length)/2. The data are presented as means ± SD of 16
tumors for each group. (b) HE staining of the subcutaneous tumors excised four weeks later. Scale bar, 100 μm. (c) Three tumors from each group were
resected, RNA was extracted and YY1 expression was measured using qRT-PCR. (d) BXPC-Vector and BXPC-YY1 cells (1.5 × 106 cells/100 μl) were
separately injected into the tail vein of each mouse. Four weeks later, lung and liver metastases were evaluated by macroscopic observation and by
histomorphology under microscopy. Scale bar, 100 μm. The arrows indicate the metastases. (* represents p < 0.05, # represents p < 0.001, compared
with the control group).
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knockdown BXPC-3 cells and control cells
To identify potential YY1 target genes in BXPC-3 cells
that might reveal the mechanism by which YY1 controls
invasion and metastasis of PDAC, we used DGE to
compare the gene expression differences between YY1
knockdown BXPC-3 cells and control cells. The ex-
pression abundance of tag-mapped genes in the data
sets was analyzed by counting the number of TPM
clean tags. We performed two biological replicates of
the DGE sequencing. Analysis of the first biological
replicate revealed 13,603 and 13,793 genes for YY1
knockdown BXPC-3 cells and control cells, respect-
ively. Analysis of the second biological replicate re-
vealed 13,924 and 14,044 genes for YY1 knockdown
BXPC-3 cells and control cells, respectively. After taking








Liver metastasis 0differential gene expression analysis. The results showed
that there were 561 genes (about 4%) that were differ-
entially expressed between the two groups (Additional
file 3: Table S3). The threshold for judging the statistical
significance of gene expression was FDR ≤ 0.001 and the
absolute value of log2 ratio ≥ 1. Of the 561 genes, 136
were upregulated and 425 were downregulated in YY1
knockdown BXPC-3 cells. Of particular interest were the
genes encoding matrix metalloproteinase 10 (MMP10),
also referred to as stromelysin 2, which was upregulated
by 3.3-fold, and its inhibitor tissue inhibitor of metallopro-
teinase 2 (TIMP2), which was downregulated by 3.2-fold.
MMP10 is a secreted proteinase that degrades the extra-
cellular matrix, and TIMP2 inhibits MMP10 activity [22].
Thus, the upregulation of MMP10 and concomitant
downregulation of TIMP2 would be predicted to disrupt
cell-cell adhesion and promote invasion and metastasist model and tail vein metastasis model
t model Tail vein metastasis model
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http://www.molecular-cancer.com/content/13/1/130of YY1 knockdown BXPC-3 cells. In addition, among the
205 upregulated genes, the pancreatic cancer-related gene
MUC4 was upregulated by 4.0-fold, indicating that YY1
may negatively regulate MUC4 gene expression. This
result is consistent with our previous study [23], which
demonstrated that YY1 inhibits MUC4 gene transcrip-
tion and expression by binding to the inhibitory element
in the MUC4 promoter. Previous studies showed that
MUC4 and ErbB2 might interact physically and trans-
duce signals intracellularly, thus promoting the migra-
tory and metastatic potential of pancreatic cancer cells
[24-26]. In addition, the myocyte-specific enhancer
factor 2C (MEF2C), a direct activator of MMP10 tran-
scription [27], was upregulated by 3.5-fold. The changes
in expression of these four genes in YY1 knockdown
BXPC-3 cells were validated by qRT-PCR. The qRT-
PCR data for these genes were consistent with those
obtained by DGE expression profiling (Additional file 4:
Figure S1). Western blotting showed that the protein
levels of MUC4, p-ErbB2, MEF2C and MMP10 were
increased in YY1 knockdown BXPC-3 cells compared
with control cells (Figure 5a). Therefore, we presume
that YY1 suppresses invasion and metastasis of pancre-
atic ductal adenocarcinoma by downregulating MMP10
in a MUC4/ErbB2/MEF2C-dependent mechanism.
GO functional enrichment analysis for differentially
expressed genes (DEGs)
To gain an insight into the possible mechanisms of the
differences in gene expression between YY1 knockdown
BXPC-3 cells and control cells, GO enrichment analysis
of the DEGs was performed. All DEGs were assigned
functionally into three groups: (1) biological process; (2)
cellular component; (3) molecular function. Within bio-
logical process, cellular process and metabolic process
represented the most abundant GO terms. Most DEGs
that corresponded to cellular component were involved
in cell and cell part. Binding and catalytic activity were
the most prevalent in molecular function (Additional
file 5: Figure S2).
Correlations between YY1 and MUC4 or MMP10 mRNA
expression in PDAC tissues
We also detected the MUC4 and MMP10 mRNA levels
in 108 PDAC samples using quantitative RT-PCR and
then analyzed the correlations between the expressions
of YY1 and MUC4 or MMP10. The results showed that
YY1 expression levels were statistically negatively cor-
related with MMP10 expression levels (r = −0.472, p <
0.001), but not statistically correlated with MUC4
expression levels (r = −0.158, p = 0.102). These results,
combined with those of the in vitro experiments, sug-
gested that YY1 may negatively regulate the expression
of MMP10, thereby inhibiting metastasis of PDAC.YY1 regulates MMP10 to affect the migrating and
invasive abilities of BXPC-3 cells
To address whether YY1 knockdown-mediated tumor
invasion is dependent on MMP10 activity, we used siRNA
experiments to knockdown MMP10 expression in vitro.
As shown in Figure 5c and 5d, cell migration was sig-
nificantly reduced when the MMP10 activity was blocked
by siRNA in YY1 knockdown BXPC-3 cells (BXPC-YY1
shRNA+MMP10 siRNA vs. BXPC-YY1 shRNA+Control
siRNA, 0.552 ± 0.040 vs. 1.188 ± 0.065, p < 0.001). Invasion
experiments also showed similar results (data not shown).
These results suggested that MMP10 plays an important
role in YY1 knockdown-mediated cell invasive and migra-
tory behaviors.
YY1 knockdown upregulates MMP10 by activating the
MUC4/ErbB2/p38 MAPK signal transduction pathway
The impact of YY1 on the major pathways of intracel-
lular signaling was studied by western blot for: ErbB2,
MAPKs (Erk1/2, JNK and p38), Akt, and Focal Adhe-
sion Kinase (FAK) (Figure 5a, 5b and Additional file 6:
Figure S3). Phosphorylation of ErbB2 and phosphoryl-
ation of p38 MAPK decreased in YY1 overexpression
BXPC-3 cells, whereas they increased in YY1 knock-
down BXPC-3 cells, compared with control cells, indi-
cating activation of ErbB2 and p38 MAPK pathways
subsequent to YY1 silencing. Erk1/2 and JNK MAPK
pathways did not appear to be significantly affected by
either YY1 overexpression or YY1 knockdown (Figure 5a
and 5b). Similarly, Akt and FAK pathways were not signifi-
cantly modified (Additional file 6: Figure S3).
We next evaluated whether the YY1 knockdown-
induced transduction molecules enhanced MMP10 ex-
pression at the level of transcriptional using luciferase
reporter activity assays. YY1 knockdown significantly
increased the luciferase activities of MMP10 and this effect
could be suppressed by MUC4 blockage, by the ErbB2 in-
hibitor AG825 (25 μM) or by the p38 inhibitor SB203580
(10 μM) in YY1 knockdown BXPC-3 cells transfected with
the MMP10 promoter (p < 0.01) (Figure 5e). These results
indicate that YY1 knockdown upregulates MMP10 by
activating the MUC4/ErbB2/p38 MAPK signal trans-
duction pathway.
MUC4/ErbB2/p38 MAPK signal transduction-mediated
MEF2C activation is involved in YY1 knockdown-induced
MMP10 expression
To elucidate whether MEF2C, a direct target of p38
MAPK [28,29] and a direct activator of MMP10 transcrip-
tion, was involved in the YY1 knockdown upregulated
MMP10 gene transcription, luciferase activity assays were
performed. The luciferase activity that was enhanced by
YY1 knockdown was significantly inhibited by the MEF2C
blockage (p < 0.001) (Figure 5f). Moreover, the luciferase
Figure 5 (See legend on next page.)
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Figure 5 Mechanisms involved in the tumor suppression role of YY1. (a) Effects of YY1 on MUC4, ErbB2, MEF2C, MMP10 and MAPK (Erk1/2,
JNK and p38) signaling pathways were assayed by western blotting. BXPC-YY1 indicates YY1overexpressing BXPC-3 cells; BXPC-Vector indicates
BXPC-3 cells transfected with a control vector; BXPC-YY1 shRNA indicates YY1 knockdown BXPC-3 cells; BXPC-Scramble shRNA indicates BXPC-3
cells transfected with a vector expressing Scramble shRNA. GAPDH was used as the internal control. (b) Bands were quantified by densitometry.
Histograms of the ratio (phosphorylated/constitutive form) for Erk1/2, JNK and p38 MAPK kinases are shown. (c) BXPC-YY1 shRNA cells were
transfected with MMP10 siRNA or negative control siRNA. 12 h after transfection, cell migration assays were performed. The upper chambers
were seeded with various cell lines. The membranes of the chambers were stained with 0.1% crystal violet. Scale bar, 100 μm. (d) Quantification
of the data from Figure 5c. OD values from three independent experiments were assessed. (e) Luciferase activities of MMP10 promoter-transfected
BXPC-Scramble shRNA or BXPC-YY1 shRNA cells treated with MUC4 siRNA or various inhibitors of signal transduction molecules. MUC4 blockage, the
ErbB2 inhibitor (AG825, 25 μM) and the p38 inhibitor (SB203580, 10 μM) significantly inhibited YY1 knockdown-stimulated luciferase activity in
BXPC-YY1 shRNA cells transfected with the MMP10 promoter. (f) The YY1 knockdown-stimulated luciferase activity could be significantly inhibited by
MEF2C blockage. Luciferase activity of MMP10 promoter in BXPC-YY1 shRNA cells was significantly decreased when the presumed MEF2C binding site
(nucleotides −881 to −890) was mutated. (*represents p < 0.05, **represents p < 0.01, # represents p < 0.001, when compared to the control group).
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BXPC-3 cells was significantly decreased when the pre-
sumed MEF2C binding site (nucleotides −881 to −890)
was mutated (p < 0.001) (Figure 5f ). These results sug-
gest that ErbB2/p38 MAPK signal transduction-mediated
MEF2C activation maybe involved in YY1 knockdown-
induced MMP10 expression.
Discussion
In this study, we found that the expression of YY1 in
PDACs was higher compared with their adjacent non-
tumorous tissues and normal pancreas tissues. However,
PDAC patients with high level overexpression of YY1
had better outcome than those with low level overex-
pression. YY1 overexpression suppressed, whereas YY1
knockdown enhanced, the proliferation, invasion and
metastatic properties of BXPC-3 cells, both in vitro and
in vivo. We also explored the potential mechanisms
underlying the tumor suppression role of YY1 and found
that YY1 suppresses invasion and metastasis of pancre-
atic cancer cells by downregulating MMP10 in a MUC4/
ErbB2/p38/MEF2C-dependent mechanism. YY1 has an
important role in many biological processes. As its name
suggests, Yin-Yang 1 activates or inactivates gene expres-
sion depending on its interacting partners. Interestingly,
its function in cancer remains controversial [3-5]. YY1
positively regulates the expression of several oncogenes,
such as c-Myc and VEGF, and negatively regulates the
expression of tumor suppressor genes, such as p53 and
E-cadherin [30-33]. On the other hand, YY1 could sup-
press tumorigenesis by upregulating tumor suppressor
genes such as HLJ1 and BRCA1, and inhibiting c-myc
function by direct interaction [34-36]. Therefore, YY1 can
act as both a tumor suppressor and an oncogene, de-
pending on tissue context, interaction partners and
downstream targets.
Several lines of evidence uncovered by the present
study and our previous study indicate that YY1 may act as
a tumor suppressor in PDAC. First, YY1 binds to the pro-
moter of MUC4 and negatively regulates the expression ofthis well-known pancreatic cancer-related gene [23].
Second, we measured the expression levels of YY1 in
108 PDAC tissue samples with paired adjacent non-
tumorous tissue and five normal pancreas tissue sam-
ples. We found that YY1 is highly expressed in PDAC
tissues. However, interestingly, PDAC patients with high
level overexpression of YY1 had better outcome than
those with low level overexpression. We presumed that
YY1 is not a causal factor of pancreatic cancer; however,
during the development of pancreatic cancer, the human
body provides feedback on increased expression of tumor
suppressor gene YY1. Tumorigenesis is a complex bio-
logical process involving multi-factors, and is a com-
petitive process of carcinogens and tumor suppressor
factors. YY1, as a tumor suppressor, could not prevent
cancer. However, YY1 could play a tumor suppressor
role in inhibiting pancreatic cancer progression. There-
fore, pancreatic cancer patients with high-level overex-
pression of YY1 show good prognosis. Thus, we could
explain this seemingly contradictory phenomenon that
the expression of YY1 in PDACs was higher compared
with their adjacent non-tumorous tissues and normal
pancreas tissues, but higher overexpression of YY1 was
associated with and predicted a better outcome in PDAC
patients. This hypothesis requires experimental validation.
Finally, we found that overexpression of YY1 inhibits
invasion and metastasis of BXPC-3 cells, both in vitro
and in vivo, which would support the better clinical out-
come of the PDAC patients with higher YY1. These
findings indicate that YY1 negatively regulates MUC4
gene expression and might serves as a tumor suppressor
in pancreatic cancer formation.
The membrane-bound mucin, MUC4, which is expressed
as early as PanIN-1A but is not expressed in the healthy
pancreas, and its membrane partner, the oncogenic
receptor ErbB2, which is frequently overexpressed in
pancreatic cancer as well as in PanINs, represent promis-
ing therapeutic targets [37,38]. Previous studies showed
that MUC4 and ErbB2 interact physically and transduce
signals intracellularly, thus promoting the migratory and
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this study, our DGE, qRT-PCR and western blotting
experiments showed that YY1 overexpression downreg-
ulated, whereas YY1 knockdown upregulated, MUC4
expression in BXPC-3 cells. In addition, phosphoryl-
ation of ErbB2 decreased in YY1 overexpression BXPC-
3 cells and increased in YY1 knockdown BXPC-3 cells.
We then attempted to identify the cellular mechanisms
and the intracellular signaling pathways under the con-
trol of MUC4 and ErbB2 partners. Our results showed
that the p38 MAPK pathway was activated in YY1
knockdown BXPC-3 cells, but not the Erk1/2 or JNK
MAPK pathways. Similarly, the Akt and FAK pathways
were not significantly modified. These findings revealed
that YY1 knockdown upregulates MUC4 expression,
leading to activation of the ErbB2/p38 MAPK signal
transduction pathway in BXPC-3 cells. In addition, we
examined the correlation between YY1 and MUC4
expression in PDAC tissue samples by qRT-PCR. The
results showed that YY1 expression was not statistically
correlated with MUC4 expression. This result was not
consistent with the in vitro result, which may reflect
tissue heterogeneity and the complexity of the regula-
tion of the MUC4 gene.
MMPs are proteinases that remodel the extracellular
matrix and have previously been implicated in cancer
metastasis and progression [39]. MMP-10 (also called
stromelysin-2) belongs to the MMP family and its ex-
pression correlates closely with metastasis and poor
prognosis in various human cancers [40]. In our study,
MMP10 mRNA and protein expression were decreased
in YY1 overexpression BXPC-3 cells and increased in
YY1 knockdown BXPC-3 cells. In addition, YY1 knock-
down significantly increased the luciferase activities of
the MMP10 promoter and this effect could be sup-
pressed by MUC4 blockage, or by inhibition of ErbB2
or p38 inhibitor, indicating that YY1 knockdown up-
regulated MMP10 by activating the MUC4/ErbB2/p38
MAPK signal transduction pathway. In the MMP10
blockage experiments, cell migration and invasion were
significantly reduced when the MMP10 activity was
blocked by siRNA in YY1 knockdown BXPC-3 cells,
indicating that YY1 knockdown BXPC-3 cells with
an activated p38 MAPK pathway results in increased
MMP10 expression, thus increasing the migratory and
invasive abilities of the cells. Moreover, in PDAC tissue
samples, YY1 mRNA expression levels were statistically
negatively correlated with MMP10 expression levels,
which was consistent with the in vitro result.
MEF2C is a MADS domain transcription factor that
regulates the development and differentiation of many
tissue types [41]. It is phosphorylated by p38 MAPK in
myocytes and macrophages [28,29]. In addition, previous
studies indicated that MEF2C promotes the transcriptionof MMP10 by binding to the upstream promoter [27].
In our study, the results showed that YY1 overexpres-
sion downregulated, whereas YY1 knockdown upregu-
lated, MEF2C expression in BXPC-3 cells. Luciferase
activity assays showed that the MMP10 promoter activity
that was enhanced by YY1 knockdown was significantly
decreased by MEF2C blockage. Moreover, mutating the
MEF2C-binding site in the MMP10 luciferase reporter
completely abolished the effect of YY1 knockdown, in-
dicating that MUC4/ErbB2/p38 MAPK signal transduc
tion-mediated MEF2C activation is involved in YY1
knockdown-induced MMP10 expression.
Conclusions
In summary, YY1 is highly expressed in all PDAC. Higher
overexpression of YY1, however, was associated with, and
predicted, a better outcome in PDAC patients. The YY1
high-level overexpression suppresses invasion and me-
tastasis of pancreatic cancer cells by downregulating
MMP10 via a MUC4/ErbB2/p38/MEF2C-dependent mech-
anism (Figure 6). Although other undiscovered mecha-
nisms maybe involved in the YY1-mediated tumor
suppression role, the present study suggested that YY1
high-level overexpression (≥1.159) plays a negative role;
i.e., acts as a tumor suppressor in PDAC. YY1 expression
levels may represent a valuable diagnostic and prognostic
marker of PDAC.
Methods
Patients and pancreatic tissues
Pancreatic tissue samples were obtained from 108 pa-
tients (average age 61.0 years; range 25–82 years) who
underwent pancreaticoduodenectomy for PDAC at the
first Affiliated Hospital of Nanjing Medical University,
China, between 2006 and 2012. No chemotherapy or
radiation therapy was administered before tumor exci-
sion. Written informed consents were obtained from all
patients undergoing surgery and the Ethics Committees of
the first Affiliated Hospital of Nanjing Medical University
approved the study. One hundred and eight pairs of
tumorous and non-tumorous tissue samples from these
patients were collected during surgery. In addition,
samples of normal pancreas tissue were obtained from
five patients who underwent partial pancreatectomy for
benign pancreatic tumors. Immediately (within 5 min)
upon surgical removal, each tissue sample was cut in
two, one was snap-frozen in liquid nitrogen until use
(for RNA or protein extraction) and the other was fixed
in 5% formalin and embedded in paraffin after 24 hr
(for immunohistochemistry). A pathologist examined all
tissue samples histologically to confirm the diagnosis.
The 108 PDAC patients were followed up regularly
until 31 May 2013. Patients’ overall survival was defined
as the time between surgery and death or the last follow-
Figure 6 Schematic representation of the roles of YY1 on the migrating and invasive properties of BXPC-3 cells. YY1 suppresses invasion
and metastasis of BXPC-3 cells by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism. “?” represents other undiscovered
mechanisms that might be involved.
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month after surgery. The clinicopathological and sero-
logical characteristics of the 108 patients are summarized
in Table 1. Tumor differentiation was assigned according
to the World Health Organization criteria [42]. TNM sta-
ging was based on the sixth edition of the American Joint
Committee on Cancer (AJCC) guidelines [43].
Quantitative RT-PCR (qRT-PCR)
Total RNAs were prepared using the TRIzol reagent
(Life Technologies, Carlsbad, CA, USA), according to
the manufacturer’s protocol. After spectrophotometric
quantification, 1 μg of total RNA was used for reverse
transcription (RT) in a final volume of 20 μl with an
iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA,
USA) according to the manufacturer’s instructions.
Quantitative PCR was performed using TaqMan Gene
Expression Assays (Life Technologies) in a StepOne
Plus Real-time PCR System (Life Technologies). The
reactions were performed in a volume of 10 μl containing
1 μl diluted cDNA, 20 × TaqMan Gene Expression Assay
Mix and 2 × TaqMan Universal PCR Master Mix. The
thermal cycling conditions comprised an initial denatur-
ation step at 95°C for 10 min, 40 cycles at 95°C for 15 s
and 60°C for 1 min. The TaqMan Gene Expression Assay
Mixes used for YY1, MMP10, TIMP2, MUC4 and MEF2C
had the product numbers Hs00231533_m1, Hs002339
87_m1, Hs00234278_m1, Hs00366414_m1 and Hs00231
149_m1, respectively. Human 18S rRNA (product number
Hs099999901_s1) or GAPDH (product number Hs02758
991_g1) were used to calibrate the original concentration
of mRNA. The relative gene expression was calculated by
the subtraction of the Ct value of YY1 (target) and 18S
rRNA or GAPDH (control) genes by the 2-ΔCT method[44]. Each quantitative PCR was performed in triplicate
and independently repeated three times.
Tissue microarrays and immunohistochemistry
To verify the YY1 expression in PDAC tissues detected
by qRT-PCR, tissue microarrays (TMA) containing five
normal pancreas tissue samples and 108 pairs of PDAC
samples and their corresponding non-tumorous tissues
(duplicate 2 mm tissue cores for each PDAC) were con-
structed by Shanghai Outdo Biotech co., Ltd (Shanghai,
China).
Immunohistochemistry was performed as follows. 4-μm-
thick TMA sections were cut and mounted on poly-L-
lysine-coated glass slides. Slides were deparaffinized in
xylene, rehydrated in graded alcohol and washed in tap
water. Endogenous peroxidase was blocked by incubat-
ing the sections in 3% H2O2 for 5 min. Antigen retrieval
was then performed for 20 min in 10 mmol/L sodium
citrate buffer (pH 6.0) heated at 95°C in a microwave
oven, followed by a blocking step with 5% normal goat
serum for 10 min at room temperature. After blocking,
the sections were incubated at 4°C overnight with anti-
YY1 polyclonal antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA, 1:150 dilution), followed by incuba-
tion with a secondary antibody (goat anti-rabbit/horserad-
ish peroxidase, Santa Cruz Biotechnology, 1:200 dilution)
at room temperature for 30 min. Finally, the sections
were developed with diaminobenzidine substrate for
about 5 min, and counterstained with hematoxylin. Two
authors (Yi Zhu and Jing-Jing Zhang) evaluated the
immunohistochemical data for YY1. Expression levels
were evaluated according to the staining intensity (0 for
absent, 1 for weak, 2 for moderate and 3 for strong
staining) and proportion of positive cells (0 for <10%, 1
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intensity and proportion scores were then used to deter-
mine the immunoreactivity.
Cell lines and cell culture
Six human PDAC cell lines (BXPC-3, PANC-1, HPAC,
CFPAC-1, SW1990 and COLO-357) were purchased from
the Shanghai Cell Bank (Shanghai, China). The cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM)
(Life Technologies) supplemented with 10% fetal calf
serum (FBS) (Wisent Inc., Montreal, Qc, Canada), 10 mM
HEPES (Sigma, St Louis, MO, USA), 2 mM L-glutamine
(Sigma), 1 mM pyruvate sodium (Sigma), 100 units/ml
penicillin (Life Technologies), and 100 μg/ml streptomycin
(Life Technologies) at 37°C in a humidified atmosphere
containing 95% air and 5% CO2.
Preparation of YY1 overexpression BXPC-3 cells
Sunbio Medical Biotechnology Co., Ltd (Shanghai, China)
constructed the YY1-overexpression lentiviruses. Briefly,
the full-length coding region of human YY1 was sub-
cloned into pCDH-CMV-MCS-EF1-Puro vector (System
Biosciences, Mountain View, CA, USA) and verified by
sequencing. The verified recombinant vector and the
pPACKH1 packaging plasmid mix (System Biosciences)
were co-transfected into 293T cells using the Lipofecta-
mine 2000 reagent (Life Technologies). The supernatant
of the cultured 293T cells was collected to infect BXPC-3
cells. The pCDH-CMV-MCS-EF1-Puro vector was used
to package the virus and infect BXPC-3 cells as a control.
Stable cell lines (BXPC-Vector and BXPC-YY1) were
selected by culturing in media containing 5 μg/ml
puromycin (Sigma). YY1 expression was confirmed by
qRT-PCR and Western blot.
Preparation of YY1 knockdown BXPC-3 cells
Sunbio Medical Biotechnology Co., Ltd (Shanghai, China)
constructed the YY1-knockdown lentiviruses. The target
DNA sequences corresponding to YY1-shRNA were
detailed in a previous report [45]. The selected sequences
were as follows: Forward oligonucleotide, 5′ccggGGGAG
CAGAAGCAGGTGCAGATctcgagATCTGCACCTGCTT
CTGCTCCCtttttg-3′; Reverse oligonucleotide: 5′ aattcaaaa
aGGGAGCAGAAGCAGGTGCAGATctcgagATCTGCAC
CTGCTTCTGCTCCC-3′, with AgeI and EcoRI restriction
enzyme sites (5′ and 3′ ends, respectively). The target
DNA was subcloned into pLKO.1-TRC Cloning Vector
(Addgene, Cambridge, MA, USA). The verified recombin-
ant vector plasmid (pLKO.1/YY1-shRNA), packaging plas-
mid psPAX2 (Addgene) and envelope plasmid pMD2.G
(Addgene) were co-transfected into 293T cells using the
Lipofectamine 2000 reagent. The supernatant of the
cultured 293T cells was collected to infect BXPC-3 cells.
The pLKO.1-scramble shRNA (Addgene, Negative controlvector containing scramble shRNA insert) was used to
package the virus and infect BXPC-3 cells as a control.
Stable cell lines (BXPC-Scramble shRNA and BXPC-YY1
shRNA) were selected by culturing in media containing 5
μg/ml puromycin (Sigma). qRT-PCR and western blotting
confirmed the YY1 expression.
Western blotting
Pancreatic cancer cells or pancreas tissue were lysed in
ice-cold lysis buffer containing the following reagents:
50 mM Tris–HCl pH 7.4; 1% NP-40; 150 mM NaCl;
1 mM EDTA; 1 mM PMSF and complete proteinase
inhibitor mixture (1 tablet per 10 ml, Roche Diagnostics
GmbH, Mannheim, Germany). The DC protein assay kit
(Bio-Rad) was used to quantify the protein concentration
in the cell lysate. Protein aliquots were electrophoresed
using 12% SDS-PAGE and transferred to a PVDF mem-
brane (Bio-Rad). Nonspecific protein interactions were
blocked by incubation in 5% nonfat dry milk in TBST
buffer [20 mM Tris–HCl, 150 mM NaCl, 0.1% Tween 20
(pH 7.6)] at room temperature for 1 h and then washed
with TBST. Membranes were then incubated at 4°C
overnight with primary antibodies in fresh blocking buffer.
The antibodies to YY1 or GAPDH were from Santa Cruz.
The antibodies to MUC4 and MEF2C were from Abcam
(Cambridge, MA, USA). Primary antibodies to phospho-
HER2/ErbB2 (Tyr1248), HER2/ErbB2, phospho-Erk1/2
(Thr202/Tyr204), Erk1/2, phospho-SAPK/JNK (Thr183/Tyr
185), SAPK/JNK, phospho-p38 MAPK (Thr180/Tyr182),
p38 MAPK, phospho-Akt (Thr308), phospho-Akt (Ser473),
Akt, phospho-FAK (Tyr397) and FAK were from Cell
Signaling Technology (Danvers, MA, USA). The anti-
body to MMP10 was from Epitomics-an Abcam Company
(Burlingame, CA, USA). The blots were then washed
and incubated with HRP-conjugated secondary anti-
bodies (Cell Signaling) for 1 h at room temperature.
The bands were visualized with Immobilon Western
Chemilum HRP substrate (Merck Millipore, Darmstadt,
Germany) using the Fluorchem E System (ProteinSimple,
Santa Clara, CA, USA). Prestained markers (Thermo
Scientific, Rockford, IL, USA) were used as internal mo-
lecular weight standards. Each blot was independently
repeated three times.
Cell Count Kit-8 (CCK-8) assay
To detect cell proliferation, we used the CCK-8 assay
(DOJINDO, Japan), according to the manufacturer’s
protocol. Cells were seeded into 96-well plates at 2 × 103/
well. At the same time of each day, 10 μl CCK-8 was
added to each well, which contained 100 μl medium.
After incubation for 3 hours, the absorbance at 450 nm
of each well was measured using a microplate reader.
Each sample had four duplicate wells and was inde-
pendently repeated three times.
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Cell migration and invasion were assessed using 24
well Millicell Hanging Cell Culture Inserts (PET mem-
branes with 8 μm pores, Merck Millipore). For inva-
sion assays, the upper surface of each insert was coated
with Matrigel (BD Bioscience Pharmingen), following
manufacturer’s protocol. Briefly, 10% (v/v) fetal bovine
serum was used as the chemoattractant in the lower
chamber. 5 × 104 cells were seeded in the upper chamber
and incubated at 37°C, with migration assessed at 24
hours and invasion at 48 hours. Non-migrating or non-
invading cells were removed from the upper surface of
the membrane by wiping with cotton-tipped swabs. Cells
on the lower surface of the membrane were stained with
0.1% crystal violet for 10 minutes and photographed. The
stained cells were then soaked in 33% acetic acid and
oscillated for 10 min. The absorbance of 33% acetic
acid containing crystal violet was then assessed using a
microplate reader (Tecan, Shanghai, China) at a 570 nm
wavelength. The OD (optical density) value indirectly
reflected the number of penetrated cells. OD values for
triplicate membranes were reported as the mean ± SD
and the experiments were repeated three times.
In the MMP10 blockage experiments, YY1 knockdown
BXPC-3 cells were transfected with MMP10 siRNA or
negative control siRNA (Life Technologies, final concen-
tration of 30 nM) using Lipofectamine 2000, according
to the manufacturer’s protocol. 12 h after transfection,
cells were seeded in the upper chamber and incubated.
Cell migration and invasion assays were performed as
described above.
In vivo tumor growth and metastasis study
Four-week-old female nude mice (BALB/cA-nu) were
purchased from the Shanghai Experimental Animal Center
(Chinese Academy of Sciences, Shanghai, China). Thirty-
two mice were randomly divided into four groups. For
the xenograft subcutaneous implant tumor model, BXPC-
Scramble shRNA and BXPC-YY1 shRNA cells were
bilaterally injected subcutaneously into the flank region of
the mice (1.5 × 106 cells/100 μl per flank), respectively.
Bidimensional tumor measurements were taken with cali-
pers once weekly. The tumor volume was calculated using
the formula (width2 × length)/2. For the tail vein metasta-
sis model, BXPC-Vector and BXPC-YY1 cells (1.5 × 106
cells/100 μl) were separately injected into the tail vein of
each mouse. Four weeks later, the mice were euthanized
and subcutaneous tumors, lungs and livers were removed
and fixed in 4% paraformaldehyde. Deparaffinized sections
were stained using HE stain by staff of the Pathology
Department of the first Affiliated Hospital of Nanjing
Medical University. The histomorphology of the tumor
samples and extent of metastasis in the lung and liver
were evaluated.Digital gene expression (DGE) sequencing
Six micrograms of total RNA were extracted from BXPC-
Scramble shRNA and BXPC-YY1 shRNA cells as described
in section 2.2. Quality and quantity analysis of total RNA,
DGE library preparation, and sequencing were carried out
at Huada Genomics Co., Ltd. (Shenzhen, China). mRNA
was purified using Oligo (dT) magnetic beads adsorption,
and then Oligo(dT) was used as primer to synthesize the
first and second-strand cDNA. The 5′ ends of tags could
be generated by two types of endonuclease: NlaIII or
DpnII. The bead-bound cDNA was subsequently digested
with restriction enzyme NlaIII, which recognizes and cuts
off the CATG sites. The fragments, except from the 3′
cDNA fragments connected to Oligo(dT) beads were
washed away and the Illumina adaptor1 was ligated to the
sticky 5′ end of the digested bead-bound cDNA fragments.
The junction of Illumina adaptor 1 and CATG site is the
recognition site of MmeI, an endonuclease with separate
recognition sites and digestion sites. It cuts 17 bp down-
stream of the CATG site, producing tags with adaptor 1.
After removing 3′ fragments with magnetic beads precipi-
tation, Illumina adaptor 2 was ligated to the 3′ ends of the
tags, producing tags with different adaptors of either end
to form a tag library. After linear PCR amplification, frag-
ments were purified by PAGE Gel electrophoresis. Finally,
two DGE sequence libraries were sequenced using Illumina
HiSeq 2000. The raw sequences were filtered to leave clean
tags and then mapped to the transcriptome, to be used as
reference sequences containing all the possible clean tags
containing CATG and 17 base-length sequences of the
reference gene sequences. The number of unambiguous
clean tags for each gene was calculated and then nor-
malized to the number of transcripts per million clean
tags (TPM) [46,47]. A rigorous algorithm was developed
to identify differentially expressed genes between the
two groups of cells, using method described previously
[48]. The p-value corresponds to differential gene expres-
sion test. The false discovery rate (FDR) was used to deter-
mine the threshold of the p value in multiple tests and
analysis. We use FDR ≤ 0.001 and the absolute value of
log2 ratio ≥ 1 as the threshold to judge the significance of
gene expression differences [49]. We perpormed two
biological replicates of the DGE sequencing and took
the average of the two before differential gene expres-
sion analysis. For gene expression profiling analysis, we
performd gene ontology (GO) enrichment analysis for
functional significance using a hypergeometric test to
map all DEGs to terms in GO database, looking for
significantly enriched GO terms in DEGs compared
with the genome background.
Construction of reporter gene plasmids
A luciferase reporter construct containing the human
MMP10 promoter (−1000/-1, upstream of translation
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vector (Promega, Madison, WI, USA). The GenScript
Biotechnology Co., Ltd (Nanjing, China) synthesized a
DNA fragment of MMP10 promoter region (including
the sites of restriction enzymes). The DNA fragment was
subcloned into the KpnI and XhoI sites of the pGL3-basic
vector to construct pGL3-MMP10-promoter (pMMP10)
recombinant plasmid and then confirmed by sequencing.
The mutant construct containing the MMP10 pro-
moter in which the presumed MEF2C binding site (nucle-
otides −881 to −890) was mutated from TTAAAAAACA
to TTAGGGGACA was also constructed. The construct
was named pMMP10-MEF2C-M.
Cell transient transfection and luciferase assay
Transfections were performed using Lipofectamine 2000,
according to the manufacturer’s protocol. Cells were plated
into 12-well cell culture plates (2 × 105/well) 1 day before
transfection. Each transfection was performed using 1 μg
luciferase reporter construct (pMMP10 or pMMP10-
MEF2C-M) plus 2.5 ng Renilla luciferase reporter vector,
pRL-SV40 as an internal control (Promega). 48 h after
transfection, cells were washed with PBS and lysed using
1× passive lysis buffer. Firefly and Renilla luciferase activ-
ities were measured with a GloMax-20/20 luminometer
(Promega) using the Dual-Luciferase Reporter Assay
System (Promega). Firefly luciferase activity was nor-
malized to the Renilla luciferase activity. Each experiment
was performed in triplicate and independently repeated
three times.
For the MUC4 or MEF2C blockage experiments, cells
were transfected with 1 μg pMMP10, 2.5 ng pRL-SV40
plus MUC4 siRNA, MEF2C siRNA or negative control
siRNA (Life Technologies, final concentration of 30 nM).
48 h after transfection, the luciferase activity was analyzed
as described above.
For the signal transduction pathways blockage experi-
ments, cells were transfected with 1 μg pMMP10 plus
2.5 ng pRL-SV40. At 12 h after transfection, the medium
was replaced and cells were treated for 24 h with 25 μM
AG825 (Merck Millipore), 10 μM SB203580 (Cell Sig-
naling Technology) or equivalent amounts of DMSO
vehicle (Sigma) as a control. The luciferase activity was
then analyzed as described above.
Statistical analysis
Statistical analysis was performed using the SPSS soft-
ware (Version 15.0). Quantitative data were presented as
mean ± SD. Differences in the mean of two samples were
analyzed by Student’s t test. Differences in YY1 mRNA
or protein levels between PDACs and their adjacent
non-tumorous tissues were analyzed using the Mann–
Whitney U test. Correlations between YY1 mRNA levels
and protein levels were analyzed by the Spearman rankcorrelation test. Correlations between YY1 mRNA levels
and MUC4 or MMP10 mRNA levels were also analyzed
by the Spearman rank correlation test. Correlations
between YY1 mRNA expression and each clinicopatho-
logical or serological variable were analyzed by the Mann–
Whitney U or Kruskal-Wallis test. Receiver operating
characteristic (ROC) curve analysis determined the YY1
expression level cut-off value for survival analysis
[50-52]. Survival distributions and overall survival rates
were determined using the Kaplan-Meier method, and
the significance of differences between survival rates
was calculated by the Log-rank test. The variables that
showed a statistically significant prognostic value in
univariate analyses were entered into a multivariate
model and excluded for p > 0.10. A stepwise selection of
factors was applied to the multivariate Cox regression
model to identify independent prognostic factors for
overall survival. In addition, owing to the small number
of mice used, the data obtained using the tumor models
were analyzed by Fisher’s exact test. All statistical tests
were two-tailed exact tests with a p < 0.05 considered
significant.
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Additional file 2: Table S2. Univariate analysis of prognostic factors in
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Additional file 3: Table S3. Differentially expressed genes between YY1
knockdown BXPC-3 cells and control cells.
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expression. Expression levels of selected genes (MMP10, TIMP2, MUC4 and
MEF2C) from DGE sequencing were studied by qRT-PCR in BXPC-Scramble
shRNA and BXPC-YY1 shRNA cells.
Additional file 5: Figure S2. GO functional enrichment analysis for
differentially expressed genes (DEGs). All DEGs were assigned functionally
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represented the most abundant GO terms. Most DEGs that corresponded to
cellular component were involved in cell and cell part. Binding and catalytic
activity were the most prevalent in molecular function.
Additional file 6: Figure S3. Effects of YY1 on FAK and Akt signaling
pathways. Western blotting was carried out for phospho-FAK, FAK,
phospho-Akt and Akt in BXPC-YY1, BXPC-YY1 shRNA and their respective
controls (BXPC-Vector and BXPC-Scramble shRNA). GAPDH was used as
the internal control.
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